Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 8.70
Ask: 9.50
Change: -0.15 (-1.62%)
Spread: 0.80 (9.195%)
Open: 9.25
High: 9.25
Low: 9.10
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Nov 2020 11:49

RNS Number : 5467E
Scancell Holdings Plc
06 November 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Scancell Holdings plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights (Issue of shares from conversion of loan notes held by Vulpes)

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights (Issue of shares from conversion of loan notes held by third parties)

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

VULPES LIFE SCIENCES FUND

City and country of registered office (if applicable)

CAYMAN ISLANDS

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

02/11/2020

6. Date on which issuer notified (DD/MM/YYYY):

05/11/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.28%

0%

14.28%

791,917,828

Position of previous notification (if

applicable)

15.37%

0%

15.37%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B63D3314

113,059,571

14.28%

SUBTOTAL 8. A

113,059,571

14.28%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Singapore

Date of completion

05/11/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFSLLELRIII
Date   Source Headline
12th Sep 20193:56 pmRNSResult of AGM
4th Sep 20197:00 amRNSFirst Collaboration Agreement for AvidiMab
20th Aug 20192:23 pmRNSNotice of AGM
20th Aug 20197:00 amRNSFinal Results for the year ended 30 April 2019
19th Aug 20197:00 amRNSUpdate on the SCIB1 Phase 2 clinical trial
7th Aug 20197:00 amRNSNotice of Final Results
1st Jul 20197:00 amRNSH1 2019 Business Update
18th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20197:00 amRNSBoard Appointment
17th Jun 201910:45 amRNSHolding(s) in Company
14th Jun 20194:41 pmRNSSecond Price Monitoring Extn
14th Jun 20194:35 pmRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSShare Subscription and Issue of Equity to Vulpes
29th May 201911:05 amRNSSecond Price Monitoring Extn
29th May 201911:00 amRNSPrice Monitoring Extension
20th May 20197:00 amRNSScancell and CRUK provide an update on SCIB2
10th May 20197:00 amRNSClinical Advisory Board and Update on Modi-1
25th Apr 20197:00 amRNSUK approval to start SCIB1 Phase 2 trial
8th Apr 20197:00 amRNSJapan patent for Moditope immunotherapy platform
21st Mar 20197:00 amRNSProfessor Lindy Durrant receives Waldenström award
20th Mar 20197:00 amRNSScancell strengthens IP portfolio
5th Mar 20196:27 pmRNSHolding(s) in Company
4th Mar 20194:40 pmRNSSecond Price Monitoring Extn
4th Mar 20194:35 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSChange of Auditor
31st Jan 20197:00 amRNSInterim Results
23rd Jan 20197:00 amRNSUpdate on Cancer Research UK's Grand Challenge
21st Jan 20197:00 amRNSAppoints Heads of Research and Manufacturing
12th Nov 20187:00 amRNSScancell to Present at Two Conferences
1st Nov 20187:00 amRNSScancell to present at Proactive Investors Forum
30th Oct 20185:18 pmRNSResults of AGM
30th Oct 20187:00 amRNSIdentification of 2nd Moditope Cancer Vaccine
24th Oct 20189:05 amRNSSecond Price Monitoring Extn
24th Oct 20189:00 amRNSPrice Monitoring Extension
24th Oct 20187:00 amRNSUpdate on SCIB1 Phase 2 Clinical Study
5th Oct 20187:00 amRNSNotice of AGM
25th Sep 20187:00 amRNSFinal Results for the year ended 30 April 2018
18th Sep 20187:00 amRNSNotice of Final Results
10th Aug 20187:00 amRNSBoard Change
9th Aug 20187:00 amRNSAgreement
25th Jul 20182:45 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSIssue of Equity
18th Jul 20187:00 amRNSScancell exercises TriGrid commercial option
23rd May 20187:00 amRNSGrant of European patent for Moditope platform
11th May 20181:11 pmRNSHolding(s) in Company
9th May 201810:12 amRNSHolding(s) in Company
8th May 20187:00 amRNSResult of the Open Offer and PDMR Shareholdings
23rd Apr 201812:43 pmRNSHolding(s) in Company
20th Apr 20184:32 pmRNSHolding(s) in Company
18th Apr 20182:29 pmRNSResult of Placing and Subscription and PDMR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.